CorMedix Inc.
$7.58
▲
0.43%
2026-04-21 06:14:00
cormedix.com
NGM: CRMD
Explore CorMedix Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$584.18 M
Current Price
$7.58
52W High / Low
$17.43 / $6.13
Stock P/E
3.58
Book Value
$5.11
Dividend Yield
—
ROCE
23.03%
ROE
66.56%
Face Value
—
EPS
$2.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
191
Beta
1.41
Debt / Equity
36.74
Current Ratio
2.11
Quick Ratio
1.94
Forward P/E
9.92
Price / Sales
1.84
Enterprise Value
$572.71 M
EV / EBITDA
3.27
EV / Revenue
1.84
Rating
Strong Buy
Target Price
$14.57
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 2. | MindWalk Holdings Corp. | $1.27 | — | $59.32 M | — | -34.42% | -58.82% | $3.25 / $0.4 | $0.23 |
| 3. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 4. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 5. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 6. | Fulcrum Therapeutics, Inc. | $7.94 | — | $552.12 M | — | -24% | -25.3% | $15.74 / $2.92 | $5.24 |
| 7. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 128.62 M | 104.28 M | 39.74 M | 39.08 M | 31.21 M |
| Operating Profit | 59.13 M | 51.35 M | 19.54 M | 20.13 M | 12.94 M |
| Net Profit | 14.02 M | 108.56 M | 19.83 M | 20.64 M | 13.46 M |
| EPS in Rs | 0.18 | 1.37 | 0.25 | 0.26 | 0.17 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 311.71 M | 43.47 M | 0 M | 0.07 M |
| Operating Profit | 150.14 M | -22.36 M | -48.96 M | -30.62 M |
| Net Profit | 163.06 M | -17.93 M | -46.34 M | -29.7 M |
| EPS in Rs | 2.06 | -0.23 | -0.59 | -0.38 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 826.14 M | 118.85 M | 82.06 M | 62.04 M |
| Total Liabilities | 420.83 M | 34.19 M | 11.92 M | 6.98 M |
| Equity | 405.31 M | 84.66 M | 70.14 M | 55.06 M |
| Current Assets | 367.05 M | 114.58 M | 79.45 M | 59.55 M |
| Current Liabilities | 174.27 M | 33.84 M | 11.4 M | 6.31 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 175.05 M | -50.62 M | -38.41 M | -24.36 M |
| Investing CF | -308.43 M | 21.23 M | -17.06 M | -3.71 M |
| Financing CF | 238.45 M | 26.32 M | 55.92 M | 17.9 M |
| Free CF | 172.79 M | -50.73 M | -38.74 M | -24.58 M |
| Capex | -2.26 M | -0.12 M | -0.33 M | -0.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 617.03% | — | -100% | — |
| Earnings Growth % | 1009.4% | 61.31% | -56.02% | — |
| Profit Margin % | 52.31% | -41.24% | — | -45409.9% |
| Operating Margin % | 48.17% | -51.43% | — | -46819.91% |
| Gross Margin % | 88.46% | 92.66% | — | 94.29% |
| EBITDA Margin % | 53.69% | -43.66% | — | -46135.32% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.